ACER-002 (celiprolol) 200 mg BID ( DrugBank: Celiprolol )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 168 | Ehlers-Danlos syndrome | 1 |
168. Ehlers-Danlos syndrome
Clinical trials : 13 / Drugs : 21 - (DrugBank : 11) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05432466 (ClinicalTrials.gov) | November 7, 2022 | 21/6/2022 | Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome | A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome | Vascular Ehlers-Danlos Syndrome | Drug: ACER-002 (celiprolol) 200 mg BID;Drug: Placebo BID | Acer Therapeutics Inc. | NULL | Recruiting | 15 Years | 64 Years | All | 150 | Phase 3 | United States |